Idasal (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride is a selective alpha‑adrenergic agonist. By stimulating alpha receptors on the blood vessels of the nasal mucosa, it causes vasoconstriction, which reduces swelling and fluid accumulation, thereby opening the nasal airway.

The appropriate dose of Idasal is determined by a qualified healthcare professional based on the patient’s age, condition, and response. Users should follow the prescriber’s instructions and the product label for the number of sprays per nostril and duration of therapy.

Safety data for Xylometazoline Hydrochloride in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider before using Idasal to weigh potential benefits against any unknown risks.

To request Idasal, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Idasal’s active ingredient, Xylometazoline, belongs to the imidazoline class, which typically offers rapid onset of action and a favorable safety profile when used short‑term. Compared with phenylephrine‑based sprays, Xylometazoline may provide longer relief with fewer systemic effects, but both classes share similar usage limits to avoid rebound congestion.

Idasal should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the spray bottle tightly closed when not in use and out of reach of children.

Idasal is administered as a nasal spray. The user gently inserts the nozzle into one nostril, depresses the pump to deliver the recommended number of sprays, repeats in the other nostril if directed, and avoids blowing the nose for a few minutes after application.

Serious risks, though rare, include rebound nasal congestion after prolonged use, elevated blood pressure, tachycardia, and severe allergic reactions such as rash, swelling or breathing difficulty. If any of these occur, discontinue use and seek medical attention promptly.

Idasal should be avoided by individuals with known hypersensitivity to Xylometazoline or any formulation component, those with uncontrolled hypertension, severe coronary artery disease, hyperthyroidism, or anyone advised by a clinician to refrain from using topical nasal decongestants.